224 related articles for article (PubMed ID: 18673167)
1. Orexin receptor antagonists: medicinal chemistry and therapeutic potential.
Roecker AJ; Coleman PJ
Curr Top Med Chem; 2008; 8(11):977-87. PubMed ID: 18673167
[TBL] [Abstract][Full Text] [Related]
2. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia.
Neubauer DN
Curr Opin Investig Drugs; 2010 Jan; 11(1):101-10. PubMed ID: 20047164
[TBL] [Abstract][Full Text] [Related]
3. Orexin receptor antagonists: a review of promising compounds patented since 2006.
Coleman PJ; Renger JJ
Expert Opin Ther Pat; 2010 Mar; 20(3):307-24. PubMed ID: 20180618
[TBL] [Abstract][Full Text] [Related]
4. Orexin receptors: pharmacology and therapeutic opportunities.
Scammell TE; Winrow CJ
Annu Rev Pharmacol Toxicol; 2011; 51():243-66. PubMed ID: 21034217
[TBL] [Abstract][Full Text] [Related]
5. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.
Coleman PJ; Cox CD; Roecker AJ
Curr Top Med Chem; 2011; 11(6):696-725. PubMed ID: 21261591
[TBL] [Abstract][Full Text] [Related]
6. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
7. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
8. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders.
Nishino S
Expert Opin Investig Drugs; 2007 Nov; 16(11):1785-97. PubMed ID: 17970638
[TBL] [Abstract][Full Text] [Related]
9. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology.
Gotter AL; Webber AL; Coleman PJ; Renger JJ; Winrow CJ
Pharmacol Rev; 2012 Jul; 64(3):389-420. PubMed ID: 22759794
[TBL] [Abstract][Full Text] [Related]
10. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial.
Hoever P; Dorffner G; Beneš H; Penzel T; Danker-Hopfe H; Barbanoj MJ; Pillar G; Saletu B; Polo O; Kunz D; Zeitlhofer J; Berg S; Partinen M; Bassetti CL; Högl B; Ebrahim IO; Holsboer-Trachsler E; Bengtsson H; Peker Y; Hemmeter UM; Chiossi E; Hajak G; Dingemanse J
Clin Pharmacol Ther; 2012 Jun; 91(6):975-85. PubMed ID: 22549286
[TBL] [Abstract][Full Text] [Related]
11. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule antagonists of the orexin receptors.
Christopher JA
Pharm Pat Anal; 2014; 3(6):625-38. PubMed ID: 25489915
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat.
Coleman PJ; Schreier JD; Roecker AJ; Mercer SP; McGaughey GB; Cox CD; Hartman GD; Harrell CM; Reiss DR; Doran SM; Garson SL; Anderson WB; Tang C; Prueksaritanont T; Winrow CJ; Renger JJ
Bioorg Med Chem Lett; 2010 Jul; 20(14):4201-5. PubMed ID: 20610153
[TBL] [Abstract][Full Text] [Related]
14. Treatment and prevention of various therapeutic conditions using OX receptor antagonistic activity (WO2012081692).
Christopher JA; Congreve MS
Expert Opin Ther Pat; 2013 Feb; 23(2):273-7. PubMed ID: 23282091
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
[TBL] [Abstract][Full Text] [Related]
16. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
Roecker AJ; Cox CD; Coleman PJ
J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
[TBL] [Abstract][Full Text] [Related]
17. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat.
Dugovic C; Shelton JE; Aluisio LE; Fraser IC; Jiang X; Sutton SW; Bonaventure P; Yun S; Li X; Lord B; Dvorak CA; Carruthers NI; Lovenberg TW
J Pharmacol Exp Ther; 2009 Jul; 330(1):142-51. PubMed ID: 19363060
[TBL] [Abstract][Full Text] [Related]
18. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
Winrow CJ; Renger JJ
Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
[TBL] [Abstract][Full Text] [Related]
19. [Recent and potential drugs for treatment of insomnia].
Terao A; Miyamoto M
Nihon Yakurigaku Zasshi; 2007 Jan; 129(1):35-41. PubMed ID: 17220574
[No Abstract] [Full Text] [Related]
20. Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1.
Sifferlen T; Koberstein R; Cottreel E; Boller A; Weller T; Gatfield J; Brisbare-Roch C; Jenck F; Boss C
Bioorg Med Chem Lett; 2013 Apr; 23(7):2212-6. PubMed ID: 23434414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
